Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Can J Gastroenterol Hepatol. 2018 Jan 17;2018:8547940. doi: 10.1155/2018/8547940. eCollection 2018.
Liver resection is the only potentially curative treatment option in patients with liver metastases from colorectal cancer, but only about 20% of the patients are resectable. Liver transplantation of patients with unresectable liver metastases was attempted in the early era but it was abandoned due to poor survival. During the last decade, several case reports, a controlled pilot study, and a retrospective cohort study indicated that prolonged disease-free survival and overall survival can be obtained in a proportion of these patients. Strict selection criteria have not yet been well defined, but tumor load, response to chemotherapy, pretransplant carcinoembryonic antigen level, and time interval from resection of the primary tumor to transplant are all factors related to outcome. Carefully selected patients may obtain 5-year overall survival that approaches conventional indications for liver transplant. The scarcity of liver grafts is a significant problem, but this can possibly to some extent be addressed by use of extended criteria grafts and novel surgical techniques. There is an increasing interest in liver transplantation in these patients in the transplant community, and currently 4 clinical trials are active and are recruiting.
肝切除术是结直肠癌肝转移患者唯一可能治愈的治疗选择,但只有约 20%的患者可切除。在早期,曾尝试对不可切除肝转移患者进行肝移植,但由于生存状况不佳而被放弃。在过去十年中,一些病例报告、一项对照性试验和一项回顾性队列研究表明,在这些患者中,一部分患者可以获得无病生存期和总生存期的延长。严格的选择标准尚未得到很好的定义,但肿瘤负荷、对化疗的反应、移植前癌胚抗原水平以及原发肿瘤切除与移植之间的时间间隔均与预后相关。经过精心挑选的患者可能获得接近肝移植常规适应证的 5 年总生存率。肝供体的缺乏是一个重大问题,但这在一定程度上可以通过使用扩展标准的供体和新的手术技术来解决。移植领域对这些患者进行肝移植的兴趣日益增加,目前有 4 项临床试验正在进行并招募患者。